Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 281.5 TWD -1.4% Market Closed
Market Cap: 74.7B TWD
Have any thoughts about
Lotus Pharmaceutical Co Ltd?
Write Note

Lotus Pharmaceutical Co Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lotus Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Lotus Pharmaceutical Co Ltd
TWSE:1795
EPS (Diluted)
NT$15
CAGR 3-Years
41%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
EPS (Diluted)
NT$3
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
4%
Formosa Laboratories Inc
TWSE:4746
EPS (Diluted)
NT$2
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
-1%
ScinoPharm Taiwan Ltd
TWSE:1789
EPS (Diluted)
NT$0
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
-7%
S
SCI Pharmtech Inc
TWSE:4119
EPS (Diluted)
NT$1
CAGR 3-Years
N/A
CAGR 5-Years
-30%
CAGR 10-Years
-8%
Standard Chem & Pharm Co Ltd
TWSE:1720
EPS (Diluted)
NT$4
CAGR 3-Years
10%
CAGR 5-Years
17%
CAGR 10-Years
11%
No Stocks Found

Lotus Pharmaceutical Co Ltd
Glance View

Market Cap
74.4B TWD
Industry
Pharmaceuticals

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of generic pharmaceutical products; and the provision of consulting services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-12-13. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The firm is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The firm mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Intrinsic Value
362.33 TWD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Lotus Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
15.2 TWD

Based on the financial report for Jun 30, 2024, Lotus Pharmaceutical Co Ltd's EPS (Diluted) amounts to 15.2 TWD.

What is Lotus Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
52%

Over the last year, the EPS (Diluted) growth was -15%. The average annual EPS (Diluted) growth rates for Lotus Pharmaceutical Co Ltd have been 41% over the past three years , 52% over the past five years .

Back to Top